Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today.
Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies – including targeted treatments, stem cell transplant, and clinical trials – are helping improve outcomes and quality of life. We also discuss the importance of supportive care and ongoing research, offering listeners a clearer picture of how AML is treated now and where progress continues to be made.
Podcast: Play in new window | Download
Subscribe: Spotify | Pandora | Blubrry | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Acute myeloid leukemia
- Allogeneic stem cell transplantation
- Clinical Trial Support Center
- Beat AML® Master Clinical Trial
- Beat AML® press release – January 2026
Additional Blood Cancer United Support Resources:
- Information Specialists
- Financial support
- Online Chat
- Free Nutrition Consultations
- Free telephone/web patient programs
- Free booklets
- Support groups
- Caregiver support
- Caregiver Workbook
- Young Adult Resources
- Survivorship Workbook
- Advocacy and Public Policy
- Patient Community
- Mental Health Resources
Episode supported by AbbVie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.